[hlHome]

0

Back to Evolving and Emerging Trends in HER2 Classification and Reporting in Breast Cancer
Evolving and Emerging Trends in HER2 Classification and Reporting in Breast Cancer

Evolving and Emerging Trends in HER2 Classification and Reporting in Breast Cancer

The emergence of HER2-low therapies for metastatic breast cancer is a paradigm shift in the traditional binary classification of a patient’s HER2 status, creating a need for practice changes in pathology necessitated by the expansion in how HER2-low breast cancer needs to be classified and treated. During this recorded 2022 ASCP Annual Meeting session, a moderated expert faculty panel will discuss evolving and emerging trends in breast cancer classification and reporting across the HER2+ spectrum. They will also discuss how pathologists and laboratory professionals can prepare for HER2-low classification, tracking, and reporting. In addition, they will review some of the current challenges in HER2 testing and explore opportunities to prepare for the future landscape of HER classification in breast cancer.

The activity offers 1.0 CME/CMLE credit.

The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

  • List Price: Free
Item Details:

The emergence of HER2-low therapies for metastatic breast cancer is a paradigm shift in the traditional binary classification of a patient’s HER2 status, creating a need for practice changes in pathology necessitated by the expansion in how HER2-low breast cancer needs to be classified and...

Back to Evolving and Emerging Trends in HER2 Classification and Reporting in Breast Cancer
View More View Less

Bought This Bought That ...